Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexell launches cell selection system in Europe:

This article was originally published in Clinica

Executive Summary

Nexell Therapeutics, a subsidiary of Vimrx Pharmaceuticals has launched its second-generation Isolex 300k cell selection system in Europe. The Irvine, California-based system is the first such product with fully automated DC34+ cell selection and breast cancer cell purging capability to have received the CE mark. The new system has an improved disposable set design which is intended to improve CD34+ cell selection performance. Last month, Nexell received an approvable letter from the US FDA for the first-generation Isolex 300I system for positive selection of CD34+ cells.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel